Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Blastic Phase Chronic Myelogenous Leukemia: early-phase trial registry
A small indexed set (8 trials) with no open enrollment listed right now.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · none currently recruiting · #2,176 of 28,707 conditions by registered trial count
Blastic Phase Chronic Myelogenous Leukemia: 8 US clinical trials tracked, none currently recruiting.
Blastic Phase Chronic Myelogenous Leukemia is the subject of 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 4 of these trials.
Enrollment posture brief
Registry condition blastic-phase-chronic-myelogenous-leukemia
OPEN 0 | RECR 0% | LATE 1 | EARLY 6 | RANK #2176 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Blastic Phase Chronic Myelogenous Leukemia has no open enrollment in this registry pull (8 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Blastic Phase Chronic Myelogenous Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Blastic Phase Chronic Myelogenous Leukemia is recruiting below its size-band peers.
0 of 8 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Blastic Phase Chronic Myelogenous Leukemia research.
National Cancer Institute (NCI) accounts for 4 of 8 trials (50%). 4 distinct sponsors appear on at least one study for this condition label.
-
Most Blastic Phase Chronic Myelogenous Leukemia trials plan to enrol fewer than 100 people.
Median target enrolment is 60 among the 8 trials that report a genuine target (sentinel values excluded). 7 of those (87.5%) plan for fewer than 100 participants.
-
Blastic Phase Chronic Myelogenous Leukemia research is mostly interventional.
8 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
8 total, page 1 of 1
Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia
Children's Oncology Group
NCT04258943
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
NCT00799461
Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
NCT00054431
CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase
National Cancer Institute (NCI)
NCT00084916
STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
NCT00015834
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Children's Oncology Group
NCT00309907
Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer
National Cancer Institute (NCI)
NCT00012376
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT00408681
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 3 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Blastic Phase Chronic Myelogenous Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Blastic Phase Chronic Myelogenous Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Blastic Phase Chronic Myelogenous Leukemia page
8 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Blastic Phase Chronic Myelogenous Leukemia trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- National Cancer Institute (NCI) sponsors the most Blastic Phase Chronic Myelogenous Leukemia trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Blastic Phase Chronic Myelogenous Leukemia condition card totals 8 registered trials; most-linked intervention laboratory biomarker analysis; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.